ICPT Stock Recent News
ICPT LATEST HEADLINES
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.
Intercept's (ICPT) NDA for obeticholic acid (OCA) gets a complete response letter (CRL) from the FDA for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
Intercept Pharmaceuticals Inc. ICPT, -1.62% on Friday said it will reduce its work force by one third as part of its plan to reach profitability in 2024. The layoffs will affect about 110 employees, based on the 341 total employees as of Dec. 31 that the Morristown, N.J.
The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for Intercept Pharmaceuticals' drug to treat a type of fatty liver disease.
Intercept Pharmaceuticals (ICPT) announces new data showing the potential of a fixed-dose combination of OCA and bezafibrate to normalize multiple biomarkers in primary biliary cholangitis.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) stock is down 19.3% at $10.95, after a Food and Drug Administration (FDA) panel voted against recommending accelerated approval for its obeticholic acid treatment for non-alcoholic steatohepatitis (NASH) -- a type of fatty liver disease.
The FDA will likely reject Intercept Pharmaceuticals' highly watched liver disease treatment, analysts said Monday as ICPT stock crashed. The post Intercept Crashes As FDA Advisors Deliver The Likely Deathblow For Its Highly Watched NASH Drug appeared first on Investor's Business Daily.
Shares of Intercept Pharmaceuticals Inc fell 16% on Monday over concerns about the prospects of the company's drug to treat a type of fatty liver disease after the regulator's advisory panel voted to defer an accelerated approval.